MCP ‐1 as a Biomarker of Vascular Function
Diabetes, Obesity and Metabolism · 16.11.2026
DOI: 10.1111/dom.71544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 16.11.2026. Verfasst von William MacDonald und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Research, Ninewells Hospital, School of Medicine, University of Dundee, Dundee, UK. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative.
Abstract (Originalsprache)
Background
Endothelial dysfunction and arterial stiffness have been shown to be associated with cardiovascular disease (CVD) outcomes but assessment of these is not straightforward. CVD risk in diabetes shows heterogeneity and new biomarkers are required to stratify CVD risk in these patients. The aim of this study was to determine the association between MCP‐1 and measures of endothelial function and large artery stiffness, independently of traditional CVD risk factors, in patients with and without Type 2 diabetes mellitus (T2DM).
Methods
This study analysed the association of monocyte chemoattractant protein‐1 (MCP‐1) with measures of vascular function in 477 patients with T2DM and 261 patients without T2DM. Endothelium‐dependent and endothelium‐independent microvascular responses were assessed by measuring vasodilator responses to iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP), respectively, using laser Doppler imaging (LDI). Large artery stiffness was measured using carotid‐femoral pulse wave velocity (cf‐PWV).
Results
MCP‐1 was inversely associated with ACh and SNP responses, in patients with and without T2DM. Each SD higher MCP‐1 was associated with lower ACh ( β = −21.7 AU, 95% CI: −34.3 to −9.0) and SNP ( β = −20.5 AU, 95% CI: −32.5 to −8.4) responses after adjustment for CVD risk factors, BMI, HbA1c, eGFR, medication and study centre, with similar associations in patients with and without T2DM. MCP‐1 was not associated with the ACh:SNP ratio or with cf‐PWV, and the associations were not modified by BMI.
Conclusion
This study shows MCP‐1 to be associated with reduced microvascular vasodilator capacity, affecting endothelium‐dependent and endothelium‐independent responses, in patients with and without T2DM, independently of adiposity. Longitudinal studies in larger cohorts are required to determine whether MCP‐1 improves CVD risk prediction and identifies patients most likely to benefit from targeted therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Research, Ninewells Hospital, School of Medicine, University of Dundee, Dundee, UK.
- Division of Population and Health Genomics, Ninewells Hospital, School of Medicine, University of Dundee, Dundee, UK.
- Vascular Research Centre, Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK.
- NIHR Exeter Clinical Research Facility, Exeter, UK.
ORCID-Profile: William MacDonald, Kim M Gooding, W David Strain
Förderung
- Innovative Medicines Initiative
Zitieren
APA
MacDonald, W., Bhattacharjee, A., Aizawa, K., Gooding, K. M., Casanova, F., Gates, P. E., Mawson, D. M., Strain, W. D., Hope, S. V., Gilchrist, M., Shore, A., & Khan, F. (2026). MCP ‐1 as a Biomarker of Vascular Function. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71544
Vancouver
MacDonald W, Bhattacharjee A, Aizawa K, Gooding KM, Casanova F, Gates PE, et al. MCP ‐1 as a Biomarker of Vascular Function. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71544
BibTeX
@article{MacDonald2026,
author = {MacDonald, William and Bhattacharjee, Atanu and Aizawa, Kunihiko and Gooding, Kim M and Casanova, Francesco and Gates, Phillip E and Mawson, David M and Strain, W David and Hope, Suzy V and Gilchrist, Mark and Shore, Angela and Khan, Faisel},
title = {MCP ‐1 as a Biomarker of Vascular Function},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71544}
}
EUVIMED